Cogent Biosciences, Inc. (COGT) has a negative trailing P/E of -7.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 34.8 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -13.18%, forward earnings yield 2.88%. PEG 0.31 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 48/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -14.4 | -0.08 | 4.97 | 40.95 | - |
| 2017 | -12.9 | -1.14 | 11.61 | 39.32 | - |
| 2018 | -3.2 | -0.05 | 1.82 | 11.25 | - |
| 2019 | -0.7 | 0.03 | 0.69 | 0.98 | - |
| 2020 | -1.7 | -0.03 | 0.53 | 15.81 | - |
| 2021 | -4.6 | 0.07 | 1.55 | 0.00 | - |
| 2022 | -4.8 | -0.22 | 2.66 | 0.00 | - |
| 2023 | -2.4 | -0.34 | 1.82 | 0.00 | - |
| 2024 | -3.2 | -1.92 | 3.16 | 0.00 | - |
| 2025 | -7.3 | -2.00 | 3.77 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-2.45 | $6.36M | $-18.12M | -285.2% |
| 2017 | $-3.45 | $8.36M | $-25.49M | -304.9% |
| 2018 | $-5.55 | $9.73M | $-34.53M | -354.8% |
| 2019 | $-3.97 | $22.5M | $-30.27M | -134.6% |
| 2020 | $-6.00 | $7.87M | $-66.45M | -844.3% |
| 2021 | $-1.85 | $0.00 | $-71.81M | - |
| 2022 | $-2.26 | $0.00 | $-132.64M | - |
| 2023 | $-2.42 | $0.00 | $-192.41M | - |
| 2024 | $-3.49 | $0.00 | $-255.86M | - |
| 2025 | $-2.55 | $0.00 | $-328.94M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.14 | $-2.85 – $-1.65 | $17.81M | $6.59M – $33.8M | 9 |
| 2027 | $-0.64 | $-2.44 – $1.64 | $359.3M | $114.34M – $773.39M | 8 |
| 2028 | $1.05 | $0.23 – $2.35 | $763.96M | $763.96M – $763.96M | 8 |
| 2029 | $3.07 | $0.37 – $7.75 | $1.31B | $421.86M – $2.84B | 6 |
| 2030 | $4.76 | $0.57 – $12.01 | $1.75B | $563.96M – $3.79B | 6 |
